Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

Fig. 2

Pathological response A. pCR in the breast of overall patients, B. pCR in the breast and axilla of overall patients, C. pCR of patients with Ki-67 ≥ 20%; D. pCR of patients with luminal A disease, E. pCR of patients with luminal B Ki-67 high disease; F. pCR of patients with TNBC disease. pCR, pathological complete response; TE, docetaxel and epirubicin; TX, docetaxel and capecitabine

Back to article page